PR Newswire
London, November 18
Bioventix plc
("Bioventix" or the "Company")
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):
| Director | Position | Ordinary Shares sold | Sale price per Ordinary Share | Ordinary Shares held subsequently | Percentage of issued share capital held subsequently |
| Ian Nicholson and Persons Closely Associated | Non-Executive Chairman | 4,000 | 1300p | 23,000 | 0.45% |
| Peter Harrison and Persons Closely Associated | CEO | 100,000 | 1300p | 508,176 | 9.96% |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| Details of the person discharging managerial responsibilities / person closely associated | ||||||||||||||||||
| a) | Names | Ian Nicholson (Non-Executive Chairman) Catherine Nicholson (PCA of Ian Nicholson) Peter Harrison (CEO) Abigail Harrison (PCA of Peter Harrison) | ||||||||||||||||
| Reason for the Notification | ||||||||||||||||||
| a) | Position/status | See 1(a) above, all are PDMR's or PCA's of PDMR's | ||||||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||||||
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||||
| a) | Name | Bioventix plc | ||||||||||||||||
| b) | LEI | n/a | ||||||||||||||||
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 5 pence ("Ordinary Shares") | ||||||||||||||||
| Identification code | GB00B4QVDF07 | |||||||||||||||||
| b) | Nature of the transaction | In each case, sale of Ordinary Shares | ||||||||||||||||
| c) | Price(s) and volume(s) | Ian Nicholson:
Catherine Nicholson:
Peter Harrison:
Abigail Harrison:
| ||||||||||||||||
| d) | Aggregated information: | Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 98,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share | ||||||||||||||||
| e) | Date of the transaction | 18 November 2016 | ||||||||||||||||
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||||||||||||||
For further information please contact:
| Bioventix plc Peter Harrison | Chief Executive Officer | Tel: 01252 728 001 |
| finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross | Corporate Finance Corporate Broking | Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
